<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574520</url>
  </required_header>
  <id_info>
    <org_study_id>C803-028</org_study_id>
    <nct_id>NCT02574520</nct_id>
  </id_info>
  <brief_title>Trial of Extended Release Bupivacaine for Pain Relief After Surgery</brief_title>
  <acronym>PERSIST</acronym>
  <official_title>A Placebo-controlled Trial (Part 1) or Active-controlled (Part 2) of SABER® Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study of SABER® -Bupivacaine, an experimental medication designed to
      relieve pain for up to 3 days after surgery. Given once by the surgeon at the end of surgery,
      SABER® - Bupivacaine delivers a locally-acting pain reliever directly to the surgical wound.

      The purpose of this study is to measure how well it works in reducing pain after laparoscopic
      cholecystectomy (surgery to remove the gall bladder) and to investigate the safety of
      SABER®-Bupivacaine (its side effects).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity using the NPRS-11 with movement</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Pain will be rated when subjects sit up from a supine position</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity using the NPRS-11 with movement</measure>
    <time_frame>0 to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IV morphine-equivalent dose of rescue opioids</measure>
    <time_frame>0 to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of Silverman's Integrated Analgesic (SIA) assessment score</measure>
    <time_frame>0 to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients taking no opioid rescue medication from PACU discharge</measure>
    <time_frame>0 to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first opioid rescue medication use after discharge from the PACU</measure>
    <time_frame>0 to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PACU discharge eligibility as assessed by modified Post-Anesthesia Discharge Scoring System (mPADSS)</measure>
    <time_frame>0 to 12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">296</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>SABER®-Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended Release Solution for instillation; SABER®-Bupivacaine /Once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solution for infiltration; Bupivacaine HCl/Once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER®-Bupivacaine</intervention_name>
    <arm_group_label>SABER®-Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective outpatient laparoscopic cholecystectomy using a
             conventional 4-port laparoscopic procedure.

          -  Must be able and willing to provide written informed consent, complete trial-related
             procedures, and communicate with the trial staff.

          -  Males and females 18 years of age or older.

          -  ASA Class I, II, or III.

          -  Patients of child-bearing potential must agree to use a medically acceptable method of
             contraception to prevent pregnancy for the duration of their participation in the
             trial.

          -  Must be living close enough to the investigative site to attend the four scheduled
             follow-up clinic visits.

        Exclusion Criteria:

          -  Pregnant or nursing females.

          -  Patients with absolute or relative contraindications to laparoscopic cholecystectomy.

          -  Patients with prior midline abdominal surgery who are at risk for adhesions that may
             complicate laparoscopic cholecystectomy and/or accurate pain assessments.

          -  Patients requiring emergency surgery or urgent surgery (fewer than 5 days between
             screening and surgery).

          -  Patients with a pre-planned overnight stay or pre-planned hospital admission.

          -  Patients scheduled for single incision, mini trocars, natural orifice transluminal
             endoscopic surgery (NOTES), robotic laparoscopic procedures, or any procedure (other
             than cholangiograms and minimal adhesiolysis) in addition to laparoscopic
             cholecystectomy.

          -  Patients with known hypersensitivity to amide local anesthetics such as bupivacaine.

          -  Patients with acute pain that is not due to cholecystitis.

          -  Patients with a history of chronic pain unrelated to gallbladder disease.

          -  Patients with ongoing depression or psychosis.

          -  Patients undergoing long-term treatment with opioids or other analgesics, including
             acetaminophen, NSAIDs, anticonvulsants (gabapentin or pregabalin), and antidepressants
             (SSRIs, SNRIs, and tricyclics), but not including daily low-dose aspirin.

          -  Patients who are being treated chronically with systemic corticosteroids or who will
             require peri-operative corticosteroids because of adrenal insufficiency (inhalational
             or topical corticosteroids are permitted).

          -  Patients who may be unsuitable for opioid administration (such as sensitivity [e.g.,
             history of severe nausea and vomiting] hypersensitivity, known history of abuse or
             addiction, or unwillingness to take prescribed rescue opioids).

          -  Use of anticoagulants and antiplatelet drugs (with exception of low dose aspirin) in
             the 1 week prior to surgery.

          -  Patients who are incapable of operating the electronic diary.

          -  Patients participating in any other trial with an investigational drug or device
             concurrently or less than 30 days prior to surgery for this trial.

          -  Patients who, in the Investigator's opinion, should not participate in the trial or
             may not be capable of following the trial procedures for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Ellis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Durect</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durect Study Site 04</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 03</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site 24</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 15</name>
      <address>
        <city>Fontana</city>
        <state>California</state>
        <zip>92335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 02</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 18</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 22</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 12</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 21</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 17</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 16</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 20</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 05</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 13</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 09</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 11</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 07</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 14</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 08</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site 01</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 23</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <disposition_first_submitted>May 23, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 23, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 25, 2018</disposition_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-operative pain</keyword>
  <keyword>opioid</keyword>
  <keyword>opioid reduction</keyword>
  <keyword>laparoscopic cholecystectomy</keyword>
  <keyword>laparoscopic surgery</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>extended release</keyword>
  <keyword>locally acting analgesic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

